chloroquine has been researched along with Common Variable Immunodeficiency in 1 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Common Variable Immunodeficiency: Heterogeneous group of immunodeficiency syndromes characterized by hypogammaglobulinemia of most isotypes, variable B-cell defects, and the presence of recurrent bacterial infections.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lo, B | 1 |
| Zhang, K | 1 |
| Lu, W | 1 |
| Zheng, L | 1 |
| Zhang, Q | 1 |
| Kanellopoulou, C | 1 |
| Zhang, Y | 1 |
| Liu, Z | 1 |
| Fritz, JM | 1 |
| Marsh, R | 1 |
| Husami, A | 1 |
| Kissell, D | 1 |
| Nortman, S | 1 |
| Chaturvedi, V | 1 |
| Haines, H | 1 |
| Young, LR | 1 |
| Mo, J | 1 |
| Filipovich, AH | 1 |
| Bleesing, JJ | 1 |
| Mustillo, P | 1 |
| Stephens, M | 1 |
| Rueda, CM | 1 |
| Chougnet, CA | 1 |
| Hoebe, K | 1 |
| McElwee, J | 1 |
| Hughes, JD | 1 |
| Karakoc-Aydiner, E | 1 |
| Matthews, HF | 1 |
| Price, S | 1 |
| Su, HC | 1 |
| Rao, VK | 1 |
| Lenardo, MJ | 1 |
| Jordan, MB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death[NCT00246857] | 5,000 participants (Anticipated) | Observational | 2007-02-12 | Recruiting | |||
| Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-lymphocyte Antigen 4 (CTLA4) Haploinsufficiency[NCT03733067] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2023-11-30 | Withdrawn (stopped due to No enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for chloroquine and Common Variable Immunodeficiency
| Article | Year |
|---|---|
AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.
Topics: Abatacept; Adaptor Proteins, Signal Transducing; Adolescent; Autoimmune Diseases; Child; Chloroquine | 2015 |
AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.
Topics: Abatacept; Adaptor Proteins, Signal Transducing; Adolescent; Autoimmune Diseases; Child; Chloroquine | 2015 |
AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.
Topics: Abatacept; Adaptor Proteins, Signal Transducing; Adolescent; Autoimmune Diseases; Child; Chloroquine | 2015 |
AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.
Topics: Abatacept; Adaptor Proteins, Signal Transducing; Adolescent; Autoimmune Diseases; Child; Chloroquine | 2015 |